Login
Companies $SRPT
$15.10 -$0.03 (0.19%) After hours
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

sarepta.com

What Do They Do?

Sells exon-skipping medicines for people with Duchenne muscular dystrophy and develops gene and RNA medicines for other rare diseases.

How Do They Make Money?

Customers pay for drug products delivered to their designated location, either through distribution customers who resell them or in direct sales to sites of care.

revenue
SegmentShareRevenue
PMO Products
Sold outright

52%
FY2022: 100%
ELEVIDYS
Sold outright

48%
FY2022: 0.0%

Who Are Their Customers?

In the U.S., PMO medicines are distributed through home-infusion specialty pharmacies and a specialty distributor serving hospitals and outpatient clinics. ELEVIDYS reaches hospitals for infusion through logistics and specialty-pharmacy partners; outside the U.S., third-party distributors distribute products in certain countries through expanded-access programs.

Do Revenues Turn Into Profits?

No. It lost $713.4M in FY2025.

Operating income, FY2025
−32% of revenue
▼ Turned to a loss vs FY2024 ($218.1M, 11%)
Net income, FY2025
−32% of revenue
▼ Turned to a loss vs FY2024 ($235.2M, 12%)
Free cash flow, FY2025
−14% of revenue
▲ +10% (Loss) vs FY2024 (−$342.7M, −18%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −5%
vs $399.4M in Q3 FY2025
Net income
▲ +44% (Loss)
vs −$50.6M in Q3 FY2025
PMO Products share of products, net vs 64.5% in Q3 FY2025
  • Aug 5, 2026 Sarepta narrowed its 2026 product revenue guidance The outlook moved from $1.2-$1.4 billion to $1.2-$1.3 billion.
  • Jul 27, 2026 Michael Severino became CEO, replacing Doug Ingram

Growing. Revenue grew 3.1x in 4 years, from $701.9M in FY2021 to $2.2B in FY2025, about 33% a year.

Partnered siRNA research The latest report adds Arrowhead-partnered siRNA programs to its RNA-targeted and gene-therapy work, with candidates aimed at neuromuscular diseases and other conditions.

Gene therapy reaches commercial sales The older report describes a Duchenne gene-therapy candidate in clinical development; the latest lists a gene therapy among its commercialized Duchenne products.

Revenue over time
PMO Products ELEVIDYS
$2B$1B$0

Who Do They Compete With?

Competes with Nippon Shinyaku, Italfarmaco, Wave Life Sciences, Dyne Therapeutics, Avidity Biosciences, Entrada Therapeutics, Regenxbio, BioMarin Pharmaceutical, Solid Biosciences, Genethon, Insmed, Capricor Therapeutics, Novartis, Arthex Biotech, PepGen, Vertex, Biohaven Pharmaceuticals, Celularity, uniQure, and PTC Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support